company background image
1AD

AdAlta ASX:1AD Stock Report

Last Price

AU$0.056

Market Cap

AU$17.0m

7D

24.4%

1Y

-30.9%

Updated

09 Dec, 2022

Data

Company Financials
1AD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

1AD Stock Overview

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia.

AdAlta Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AdAlta
Historical stock prices
Current Share PriceAU$0.056
52 Week HighAU$0.092
52 Week LowAU$0.042
Beta0.62
1 Month Change19.15%
3 Month Change19.15%
1 Year Change-30.86%
3 Year Change-46.67%
5 Year Change-74.54%
Change since IPO-80.00%

Recent News & Updates

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Nov 16
Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Sep 02
Is AdAlta (ASX:1AD) Using Debt Sensibly?

Recent updates

Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Nov 16
Shareholders May Find It Hard To Justify Increasing AdAlta Limited's (ASX:1AD) CEO Compensation For Now

Is AdAlta (ASX:1AD) Using Debt Sensibly?

Sep 02
Is AdAlta (ASX:1AD) Using Debt Sensibly?

We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Jun 11
We're Not Very Worried About AdAlta's (ASX:1AD) Cash Burn Rate

Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Feb 26
Companies Like AdAlta (ASX:1AD) Are In A Position To Invest In Growth

Shareholder Returns

1ADAU BiotechsAU Market
7D24.4%-0.6%-2.5%
1Y-30.9%-5.4%-5.2%

Return vs Industry: 1AD underperformed the Australian Biotechs industry which returned -5.4% over the past year.

Return vs Market: 1AD underperformed the Australian Market which returned -5.2% over the past year.

Price Volatility

Is 1AD's price volatile compared to industry and market?
1AD volatility
1AD Average Weekly Movement9.5%
Biotechs Industry Average Movement8.8%
Market Average Movement8.9%
10% most volatile stocks in AU Market15.8%
10% least volatile stocks in AU Market4.1%

Stable Share Price: 1AD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: 1AD's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aTim Oldhamhttps://adalta.com.au

AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company’s lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd.

AdAlta Limited Fundamentals Summary

How do AdAlta's earnings and revenue compare to its market cap?
1AD fundamental statistics
Market CapAU$16.97m
Earnings (TTM)-AU$6.06m
Revenue (TTM)AU$2.75m

6.4x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1AD income statement (TTM)
RevenueAU$2.75m
Cost of RevenueAU$260.61k
Gross ProfitAU$2.49m
Other ExpensesAU$8.55m
Earnings-AU$6.06m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.019
Gross Margin90.54%
Net Profit Margin-220.11%
Debt/Equity Ratio74.4%

How did 1AD perform over the long term?

See historical performance and comparison